Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396492 | 0.86 | ADORA3 (0.46) | ADORA3ADORA2AADORA1PIK3CDPIK3CA | |
| SCHEMBL2398723 | 0.85 | PIK3CD (0.41) | PIK3CDPIK3CAPIK3CBPIK3CGCLK1 | |
| SCHEMBL2396635 | 0.84 | PIK3CD (0.43) | ADORA3ADORA2AADORA1PIK3CDPIK3CA | |
| SCHEMBL2398019 | 0.83 | PIK3CD (0.39) | ADORA3ADORA2AADORA1PIK3CDPIK3CA | |
| SCHEMBL2396456 | 0.83 | PIK3CD (0.39) | ADORA3ADORA2AADORA1PIK3CDPIK3CA | |
| SCHEMBL48534 | 0.81 | PIK3CG (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPI4KB | |
| SCHEMBL1895171 | 0.80 | ADORA3 (0.52) | ADORA3ADORA2AADORA1PIK3CDPIK3CA | |
| Sulfuric Acid SCHEMBL17203250 | 0.80 | PIK3CG (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGPI4KB | |
| SCHEMBL2398905 | 0.80 | PIK3CD (0.63) | ADORA3ADORA2AADORA1PIK3CDPIK3CA | |
| SCHEMBL48826 | 0.79 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | ADORA3 723/4885ADORA2A 2787/4885ADORA1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.